Peripheral Androgen Blockade Feasible for PSA Relapse

Share this article:

Peripheral androgen blockade with a combination of finasteride and flutamide is feasible for prostate cancer patients who experience biochemical failure after definitive local therapy, researchers reported online ahead of print in Cancer.

In a study, 99 such patients received finasteride 5 mg orally per day and flutamide 250 mg orally three times a day. Investigators observed an 80% or greater decline in PSA in 96 patients (96%). Five-year overall survival was 87%. Toxicities were mild.

The researchers, led by J. Paul Monk, MD, of The Ohio State University School of Medicine in Columbus, noted that “because testosterone levels are not suppressed, this approach may be associated with less morbidity than conventional gonadal androgen suppression.”

Share this article:
You must be a registered member of RUN to post a comment.
close

Next Article in Prostate Cancer

More in Prostate Cancer

Substance Abuse May Worsen Advanced Prostate Cancer Outcomes

Substance Abuse May Worsen Advanced Prostate Cancer Outcomes

Patients with substance use disorder are more likely to be hospitalized and to make emergency department visits.

Biking Tied to PCa, But Not Reproductive Health

Biking Tied to PCa, But Not Reproductive Health

Experts note study findings aren't definitive, and risk is minimal.

Lethal Prostate Cancer Linked to Vasectomy

Lethal Prostate Cancer Linked to Vasectomy

Study finds a 19% increased risk of distant metastases or death from the cancer.